Zobrazeno 61 - 70
of 1 423
pro vyhledávání: ''
Autor:
Takumi Kishimoto, Yutaro Kaneko, Toyoaki Hida, Yuichiro Ohe, Masayuki Takeda, Masayuki Yamada, Kazuhiko Nakagawa, Chikao Morimoto, Hidehito Horinouchi, Junichi Shimizu, Takashi Seto, Itaru Miyashita, Kaname Nosaki
Publikováno v:
Lung Cancer. 137:64-70
Objectives CD26 is a transmembrane glycoprotein with dipeptidyl peptidase IV activity that is overexpressed in malignant pleural mesothelioma (MPM). We performed a phase I study to determine the maximum tolerated dose, pharmacokinetics, and antitumor
Autor:
Camille Mehlman, Etienne Giroux Leprieur, Valérie Gounant, Pierre Olivier Schischmanoff, Gaelle Rousseau-Bussac, Thierry Chinet, B. Duchemann, Jean Trédaniel, Cécile Dujon, Nicolas Girard, Jacques Cadranel, Céline Callens, Roger Lacave, Anaïs Pujals, Nathalie Théou-Anton, Hélène Blons, Sylvie Friard
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, Elsevier, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, Elsevier, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
International audience; Objectives: The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC).Mate
Publikováno v:
Lung Cancer. 137:123-128
Our study aimed to investigate the independent prognostic values of consolidation-to-tumor ratio (CTR) and tumor disappearance ratio (TDR) after adjustment for the conventional prognostic factors and the eighth edition clinical T category for patient
Autor:
Maged Hassan, Ioannis Psallidas, Najib M. Rahman, Rachel M. Mercer, David J. McCracken, Robert F. Miller, Eihab O Bedawi, Rachelle Asciak, Hany Shaarawy, Nick A Maskell, Anwar El-Ganady
Publikováno v:
Lung Cancer. 137:14-18
Objectives Recent observations indicate a potential survival benefit in patients with malignant pleural effusion (MPE) who achieve successful pleurodesis in comparison to patients who experience effusion recurrence post pleurodesis. This study aimed
Autor:
Claudia Proto, Alessandro De Toma, Giuseppe Lo Russo, Nicoletta Zilembo, Marina Chiara Garassino, Benedetta Trevisan, Arsela Prelaj, Filippo Pagani, Giulia Galli, Roberto Ferrara, Monica Ganzinelli, Filippo de Braud, Giovanni Randon, Diego Signorelli
Publikováno v:
Lung Cancer. 137:38-42
Most trials with Immune Checkpoint Inhibitors (ICIs) for Non-Small Cell Lung Cancer (NSCLC) included only small subgroups of patients aged ≥65. As NSCLC is often diagnosed in patients aged ≥70, real-world data about efficacy and safety of immunot
Autor:
Primo N. Lara, M. Phillip DeYoung, Xiaowei Wang, Sergey Orlov, Enriqueta Felip, James Vasquez, Katherine Baker-Neblett, Manuel Domine, Nina Karaseva, Ulrik Lassen, Li Yan, Daniel Morgensztern, Pilar Garrido, Jose Manuel Trigo, Paul K. Paik, Marina Shomova, Ionel Mitrica, Ignacio Delgado, Olga Burdaeva
Publikováno v:
Lung Cancer. 136:74-79
Objectives GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule i
Autor:
Konstantinos N. Syrigos, Mark A. Socinski, Wei Zhang, Dimitrios Mavroudis, Liza C. Villaruz, Jong Seok Kim, Manuel Cobo
Publikováno v:
Lung Cancer. 136:52-56
Objectives Necitumumab is a second-generation, recombinant, human IgG1-type monoclonal antibody directed against EGFR approved for adult patients with metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplati
Autor:
Dong Wook Shin, Jong Ho Cho, Su Min Jeong, Dong Woog Yoon, Sang Hyun Park, Jeong Hoon Yang, Kyungdo Han
Publikováno v:
Lung Cancer. 136:115-121
Objectives With advances in lung cancer treatments, the number of lung cancer survivors has increased. As cardiovascular diseases (CVD) are some of the major causes of non-cancer deaths, CVD management is an integral part of cancer survivorship care.
Publikováno v:
Lung Cancer. 136:37-44
Purpose The purpose of this study was to elucidate the clinicopathologic and lymph node metastatic characteristics in patients with adenocarcinoma manifested as persistent ground glass mass (GGM, ground glass opacity [GGO] exceeding 3 cm in diameter)
Autor:
Youngjoo Lee, Nak Jung Kwon, Sung-Ho Goh, Jae Hyun Jeon, Jin Ho Choi, Moon Soo Kim, Hanseong Roh, Geon Kook Lee, Hee Chul Yang, Ji Young Yun, Ji Youn Han, Jong Mog Lee
Publikováno v:
Lung Cancer. 136:15-22
Accumulating evidence reveals the association between the risk of never-smoker lung cancer and family history of cancer. However, the clinicogenomic effect of family history of cancer in never-smoker lung cancer remains unknown.We screened 3,241 lung